Related Experiment Videos
Thrombophilia, polymorphisms, and vascular disease
T C Sykes1, C Fegan, D Mosquera
1Academic Vascular Unit, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK.
Molecular Pathology : MP
|February 24, 2001
Summary
Genetic factors influence thrombosis risk, but evidence is conflicting. Only Factor V Leiden and prothrombin gene variations show clear links to venous thrombosis, often interacting with smoking. Future research needs larger, diverse studies.
Area of Science:
- Genetics
- Hematology
- Cardiovascular Medicine
Background:
- Thrombophilia traditionally signifies rare inherited coagulation defects impacting the venous system.
- Recent research explores genetic polymorphisms in prothrombotic genes for their role in both venous and arterial thrombosis.
- Existing evidence stems from numerous, often small and heterogeneous, case-control studies with varied endpoints.
Purpose of the Study:
- To investigate the impact of genetic polymorphisms in prothrombotic genes on venous and arterial thrombosis.
- To clarify the associations between specific genetic variations and thrombotic events.
- To understand gene-environment interactions, particularly with cardiovascular risk factors like smoking.
Main Methods:
- Review and synthesis of case-control association studies.
- Analysis of data from studies with diverse endpoints including deep venous thrombosis, myocardial infarction, and stroke.
- Examination of potential interactions between genetic polymorphisms and established cardiovascular risk factors.
Main Results:
- Conflicting and inconclusive data exist for many polymorphisms.
- Factor V Leiden and prothrombin gene polymorphisms demonstrate clear associations with venous thrombosis.
- Interactions between polymorphisms and risk factors like smoking significantly elevate thrombotic episode risk.
Conclusions:
- Genetic polymorphisms, particularly Factor V Leiden and prothrombin variations, play a role in venous thrombosis.
- Gene-environment interactions, especially with smoking, are critical in modulating thrombotic risk.
- Future research requires larger sample sizes, standardized clinical endpoints, and consideration of race and gene-environment interactions for robust findings.